Our Mission
To extend healthspan in companion animals through evidence-based longevity medicine, rigorous science, and compassionate care.
Vision
To establish veterinary longevity medicine as a standard of care, with data-driven protocols accessible to all practitioners.
Clinical Excellence
Deliver best-in-class longevity interventions with transparent outcomes tracking and continuous protocol refinement.
Research Leadership
Conduct and publish clinical research that advances the field of veterinary longevity medicine.
Education & Training
Train veterinarians worldwide in longevity medicine principles, diagnostic interpretation, and intervention protocols.
Industry Standards
Establish evidence-based standards for longevity interventions, biomarker interpretation, and outcome measurement.
Our Approach
Evidence-Based Medicine
Every intervention is grounded in published research, clinical data, and mechanistic understanding. We follow the evidence, not trends.
Individualised Protocols
No two dogs are identical. We develop personalised protocols based on genetics, biomarkers, medical history, and owner goals.
Continuous Monitoring
Longevity medicine requires longitudinal data. We track biomarkers over time to refine protocols and demonstrate outcomes.
Transparent Communication
We explain the science, acknowledge uncertainties, and ensure owners make informed decisions about their pets' care.
Leadership Team
Our founders bring cutting-edge human longevity research to veterinary medicine, pioneering the application of breakthrough cellular reprogramming, polyphenol therapies, and biomarker science to extend healthspan in companion animals.
Boris Djordjevic
Boris brings over 15 years of experience in ageing research and regenerative medicine to veterinary longevity care. As founder of 199 Biotechnologies, he pioneered breakthrough therapies in partial reprogramming and polyphenol research. At The Continuum Clinic, he applies this expertise to extend healthspan in companion animals through evidence-based longevity protocols.
- •Founder of 199 Biotechnologies
- •15+ years in ageing research and autologous treatments
- •Pioneer in partial reprogramming therapies
- •Cellular reprogramming and epigenetic modulation
- •Polyphenol-based longevity interventions
- •Biomarker-guided protocol development
Dr. Avi Roy
Dr. Roy is an Oxford-based biomedical scientist with expertise in translational longevity research. As CTO of BioViva Sciences and Research Fellow at the University of Buckingham's Institute for Translational Medicine, his work in skin rejuvenation, aging biomarkers, and gene therapy informs The Continuum Clinic's scientific protocols for companion animal healthspan extension.
- •PhD in biomedical rejuvenation and aging biomarkers
- •Research Fellow, University of Buckingham
- •CTO at BioViva Sciences (human longevity)
- •Aging biomarker identification and validation
- •Small molecule rejuvenation therapies
- •Translational medicine and policy development
Facilities & Accreditations
Clinic
Purpose-built facility in London with advanced diagnostic and treatment capabilities.
- •Molecular diagnostics laboratory
- •Sterile gene therapy administration suite
- •AI-powered biomarker analysis platform
- •Climate-controlled storage for biologics
Accreditations
Committed to the highest standards of veterinary care and research integrity.
- •RCVS Practice Standards Scheme
- •GMP compliance for cell therapy protocols
- •Institutional biosafety certification
- •Certified laboratory diagnostic services
Location
Based in London. Global partner network.